Therapeutic Mechanism of Clinical Grade Pcmscs on Immune Modulation and Lung Regeneration in Acute Phase of Ali/Ards( I )

Project: A - Government Institutionb - National Science and Technology Council

Project Details

Description

病毒(流感或COVID-19)或細菌感染引起的急性肺損傷和急性呼吸窘迫症候群(ALI/ ARDS)是現今重大醫療未滿足疾病,死亡率相當高但卻無有效藥物療法。間質幹細胞(MSCs)因具有效調節免疫與修復損肺損傷能力,被高度期待為新興治療策略。然而傳統實驗室與臨床級GTP實驗室細胞培養條件的差異造成不同MSC特性,導致臨床試驗效果不彰;此外所用MSCs是否具促腫瘤性亦是臨床關注議題。本研究以全身安全性臨床級異體pcMSC細胞結合體學研究 (Omic research),建立臨床級異體間質幹細胞精準治療分子圖譜,將有助於COVID-19時代大量ALI / ARDS患者的緊急精準細胞治療需求。
StatusFinished
Effective start/end date8/1/217/31/22

Keywords

  • Precision stem cell therapy
  • Acute respiratory distress syndrome (ARDS)
  • Neutrophils
  • Vascular endothelial cell adhesion molecules
  • Lung alveolar progenitor epithelium AT2 cells
  • Secretome
  • Extracellular vesicles (EVs)
  • Epigenome